KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Current Assets for 8 consecutive years, with $303.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 12.0% to $303.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $303.9 million through Dec 2025, down 12.0% year-over-year, with the annual reading at $333.0 million for FY2025, 3.98% down from the prior year.
  • Current Assets for Q4 2025 was $303.9 million at Twist Bioscience, down from $333.0 million in the prior quarter.
  • The five-year high for Current Assets was $664.4 million in Q1 2022, with the low at $303.9 million in Q4 2025.
  • Average Current Assets over 5 years is $451.7 million, with a median of $407.2 million recorded in 2023.
  • Peak annual rise in Current Assets hit 133.66% in 2021, while the deepest fall reached 39.31% in 2021.
  • Over 5 years, Current Assets stood at $385.0 million in 2021, then skyrocketed by 40.74% to $541.9 million in 2022, then dropped by 27.98% to $390.2 million in 2023, then fell by 11.51% to $345.3 million in 2024, then fell by 12.0% to $303.9 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $303.9 million, $333.0 million, and $339.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.